Lidocaine

Alternative Names: lidocaine, lignocaine, xylocaine, lidoderm, xylocain, zingo, emla cream, versatis, promescent, lidoderm 5, xylocaine 2%, alphacaine, LIDOCAINA, lidocain, ztlido, akten, glydo, lidopen, anestacon, laryng-o-jet kit, lta ii kit, pediatric lta kit, dentipatch, laryngotracheal anesthesia kit, sx1 medicated post-operative system, lmr plus, lidomark 1/5, lidomark 2/5, lidenzal 1%, lidenzal 2%, prelidopine pre-operative system, lidovix l, venipuncture px1, medicated buccal dna collection kit 2, dermalid, dx1 oragenomic medicated dna collection screen, dx2 oragenomic medicated dna collection screen, medicated buccal dna collection kit, pliaglis, lignospan standard, oraqix, lignospan forte, synera, emla, duocaine, embolex, lidosite topical system kit, iontocaine, lidocaton, octocaine, rocephin kit, lanabiotic, fossaoprin spg2, acunistat-30, acunistat-60, fossaoprin spg4, h-paxin, diclovix, omnitrenidol, lixtraxen 1%, point of care l2, diclovix m, point of care l5, point of care lm 2.2, point of care lm 2.5
Latest Update: 2024-12-19
Latest Update Note: Clinical Trial Update

Product Description

LIDOCAINE (LYE doe kane) is an anesthetic. It causes loss of feeling in the skin and surrounding tissues. It is used to prevent and to treat pain from some procedures. This medicine is also used to treat minor burns, scrapes and insect bites. (Sourced from: https://my.clevelandclinic.org/health/drugs/19854-lidocaine-skin-cream-or-ointment)

Mechanisms of Action: Sodium Channel Blocker

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous,Topical,Transdermal

FDA Designation: None *

Approval Status: Approved

Approved Indications: Neuralgia | Pain Unspecified | Anastesia Related

Company: ZARS Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Lidocaine

Countries in Clinic: Australia, Canada, China, Germany, Japan, Norway, Spain, United Kingdom, United States, Unknown Location

Active Clinical Trial Count: 18

Highest Development Phases

Phase 2: Chronic Pain|Ileus|Infertility|Pelvic Pain

Phase 1: Idiopathic Pulmonary Fibrosis|Lung Diseases, Interstitial|Neuralgia|Progressive Pulmonary Fibrosis|Skin Ulcer

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success
ORE001PIIPOI	P2	Recruiting	Ileus	2025-12-31
jRCT2031240211	P3	Recruiting	Neuralgia, Postherpetic	2025-06-30
M21-784	P3	Active, not recruiting	Neuromyelitis Optica	2025-05-28	82%
PVX 2024-01	P2	Unknown Status	Anesthesia Related	2024-12-31

Date	Type	Title
12/16/2024	News Article	Scilex Holding Company Announces Early Installment Payment on its Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation
12/13/2024	News Article	Scilex Holding Company Announces Closing of $17 Million Registered Direct Offering
12/12/2024	News Article	Scilex Holding Company Announces $17 Million Registered Direct Offering
12/10/2024	News Article	NeuroBiogen Company and Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company enter into Binding Term Sheet for Worldwide License, Along with the Rights to Sublicense for All of KDS2010 indications; Binding Term Sheet Includes Collaboration for Development and Commercialization of Novel Oral Tablet KDS2010 in Ongoing Phase 2 CardioMetabolic and Neurodegenerative Diseases

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions